Beyond the Standard: Individualized Approaches to Dual Antiplatelet Therapy Gain Attention
Dirk Sibbing, Professor, Cardiologist and Angiologist at Privatklinik Lauterbacher Mühle and LMU Munich, shared an insightful post on LinkedIn:
”When it comes to dual antiplatelet treatment we are still using a non-individualized approach in our everyday clinical practice for patients after PCI.
However, evidence is accumulating that sex, age, BMI and many more variables may constitute relevant treatment effect modifiers for drugs like clopidogrel, prasugrel or ticagrelor.
See the latest data on DAPT and sex in the European Heart Journal and my Editorial that puts the findings into perspective.”
Read the full article here.
Article: Dual antiplatelet therapy modulation strategies beyond standard of care: a promising path towards individualized antiplatelet treatment
Author: Dirk Sibbing

Stay updated on all science in the field of hematology with Hemostasis Today.
-
Nov 19, 2026, 12:34Edward Lee Carter: Are We Ready for FXIa Inhibitors?
-
Nov 19, 2026, 12:19Essama Telli: When a Bruise Doesn’t Heal – Recognising the Warning Signs
-
Nov 19, 2026, 11:51Wolfgang Miesbach: Beyond Episomal Gene Therapy in Haemophilia B
-
Nov 19, 2026, 11:18A First Look at WFH CCS 2027
-
Nov 19, 2026, 10:58Does a Higher Measured Factor Level Always Mean Better Protection Against Joint Bleeds? – Global Hemophilia Report
-
Nov 19, 2026, 10:43Strengthening Plasma Management and Patient Access Across Eastern Europe – ISBT
-
Nov 19, 2026, 10:32Rana Al-Hrout: The Hemodilution Trap – Accurate Blast Assessment in Bone Marrow Biopsies
-
Nov 19, 2026, 10:29Maria Panagiota Terzi: Presenting Research on Coagulation Biomarkers in Acute Myocardial Infarction
-
Nov 19, 2026, 10:21Paola Ranalli: Hemophilia and von Willebrand Disease Advancing Care Through Multidisciplinary Collaboration